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Abstract: Despite great advances in our knowledge of the consequences of Zika virus to human health,
many questions remain unanswered, and results are often inconsistent. The small sample size of
individual studies has limited inference about the spectrum of congenital Zika manifestations and the
prognosis of affected children. The Brazilian Zika Cohorts Consortium addresses these limitations by
bringing together and harmonizing epidemiological data from a series of prospective cohort studies
of pregnant women with rash and of children with microcephaly and/or other manifestations of
congenital Zika. The objective is to estimate the absolute risk of congenital Zika manifestations
and to characterize the full spectrum and natural history of the manifestations of congenital Zika in
children with and without microcephaly. This protocol describes the assembly of the Consortium
and protocol for the Individual Participant Data Meta-analyses (IPD Meta-analyses). The findings
will address knowledge gaps and inform public policies related to Zika virus. The large harmonized
dataset and joint analyses will facilitate more precise estimates of the absolute risk of congenital Zika
manifestations among Zika virus-infected pregnancies and more complete descriptions of its full
spectrum, including rare manifestations. It will enable sensitivity analyses using different definitions
of exposure and outcomes, and the investigation of the sources of heterogeneity between studies
and regions.
Keywords: cohort; Zika; pregnant women; microcephaly; congenital Zika syndrome; IPD meta-
analysis
1. Introduction
Between August and October 2015, the Brazilian Ministry of Health identified a
notable increase in microcephaly cases, initially in the state of Pernambuco. The largest
number of cases was registered in this state, followed by the states of Paraíba and Bahia.
On 10 November 2015, the Ministry of Health declared a Public Health Emergency of
National Importance, and in February 2016, the World Health Organization declared a
Public Health Emergency of International Concern, which was maintained until November
of the same year.
Since the onset of the microcephaly epidemic, there has been intense mobilization by
the academic community and national and international institutions, resulting in major
advances in understanding of the human health consequences of intrauterine and postnatal
exposure to Zika virus (ZIKV) infection. Investigations in Brazil provided the initial
characterization of Congenital Zika Syndrome (CZS) [1–3] and the first clinical descriptions
of microcephaly and the associated central nervous system (CNS) imaging [4,5] and of
ocular manifestations [6] (later detailed in Ventura et al. [7–9], Freitas et al. [10]). In the area
of laboratory diagnosis, researchers delineated the role of IgM in cerebrospinal fluid as a
diagnostic tool [11] and developed an algorithm for integrating longitudinal molecular and
serological assay results for defining ZIKV infections in pregnant women with rash [12].
In Pernambuco state, findings from the first microcephaly case control study contributed
key evidence supporting the causal role of ZIKV in the microcephaly epidemic [13,14].
In parallel, the Rio de Janeiro cohort of pregnant women provided the first assessment
of CZS risk after intrauterine exposure and reported heightened risks at early stages of
gestation [15,16].
Despite advances made, many key epidemiological questions remain unanswered, and
results between studies have demonstrated wide variation in the estimates of the absolute
risk of congenital Zika manifestations following confirmed maternal ZIKV infection during
pregnancy. For example, in the study by Brasil et al. [16], adverse pregnancy outcomes were
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found in 46% of the 125 pregnancies of women positive for ZIKV, while 49 of the 117 live
births (42%) had abnormalities by physical examination and/or imaging. In the study by
Rice et al. [17], 203 children (14%) born to 1450 RT-PCR-positive pregnant women in the
United States were born with a Zika-associated birth defect and/or a neurodevelopmental
abnormality possibly due to Zika virus infection. Hoen et al. [18] found a frequency of
neurological and ocular changes possibly associated with ZIKV infection in 39 (7.0%)
fetuses and children born to 546 pregnant women with a confirmed RT-PCR diagnosis
residing in the French territories of the Americas. Though the difference with the study of
Rice et al. [17] should be interpreted with caution as it is based on surveillance data, the
differences between the two prospective cohorts are even more marked.
The reasons for this heterogeneity may be explained by regional or biological differ-
ences between study populations as well as by variations in methodological approaches.
For instance, local variability in the mosquito endemicity, public health control efforts,
pre-existing immunity, and population density may alter the course of the epidemic and
the number of individuals infected but would not modify the risk of adverse outcomes in
women already infected. On the other hand, methodological differences in exposure and
outcome case definitions as well as variation in assessment techniques and instruments
may have occurred. Differences in risk estimates between studies may also have arisen due
to low precision due to small samples sizes of individual investigations. It is also worth
mentioning that, due to the relatively small samples of the cohorts of pregnant women, it is
likely that some of the rare outcomes were missed in individual studies. The Zika Brazilian
Cohorts (ZBC) Consortium (ZBC Consortium) was assembled to begin to overcome these
challenges and to improve understanding of the impact of ZIKV infections in pregnancy.
The ZBC Consortium complements two other planned joint analyses of ZIKV infec-
tions in pregnancy: the World Health Organization-led Zika Virus Individual Participant
Data Consortium [19] and the joint analysis of the prospective cohort studies of the Eu-
ropean Commission-funded Zika Preparedness Latin American Network (ZikaPLAN),
ZIKAlliance and ZIKAction consortia [20]. Though there is some overlap in the cohorts
included in the three planned analyses, there are also important distinctions in the rep-
resented populations and analytical approaches. The ZBC Consortium differs from the
others because of the relatively large sample size of some of the included cohort studies and
because of the large number of individuals from the same country (i.e., Brazil) that are being
included. These features will facilitate better exploration of within- and between-study
heterogeneity and to compare subgroups of children with different characteristics who
were evaluated using similar clinical approaches. The large sample size will also allow us
to obtain more precise estimates and to study more adequately rare events.
Since the beginning of the microcephaly epidemic, there has been great concern
in Brazil regarding the standardization of protocols and data collection instruments for
studying congenital Zika manifestations. With the support of Pan American Health Or-
ganization/World Health Organization (PAHO/WHO), a meeting of Brazilian and Latin
American researchers was held in March 2016 to consolidate efforts to harmonize study
protocols and instruments. Further discussions with international investigators were also
held during subsequent protocol harmonization meetings held in Mexico in June 2016
and Geneva in February 2017. In October 2017, the Brazilian Ministry of Health and its
Secretaries of Science, Technology, and Strategic Inputs (Secretaria de Ciência, Tecnologia e
Insumos Estratégicos-SCTIE), Health Surveillance (Secretaria de Vigilância em Saúde-SVS)
and Health Care (Sistema de Assistência à Saúde-SAS) hosted a “Zika-related Cohorts
Consortium Meeting” in October 2017, which brought together Principal Investigators
of studies at advanced stages of data collection from different regions of the country to
initiate a new national partnership known as the Zika Brazilian Cohorts Consortium (ZBC
Consortium). The early efforts of Brazilian researchers to harmonize cohort study protocols
helped to make the resultant data more compatible, more alike, facilitating the planned
pooled analysis.
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The ZBC Consortium brings together and harmonizes epidemiological data from a
series of prospective cohort studies, initiated during the 2015–2016 ZIKV epidemic, of
pregnant women with rash and of children with microcephaly and/or other manifestations
of congenital Zika. During four face-to-face meetings, principal investigators of the cohort
studies have worked to: (1) elaborate a database management and authorship agreement;
(2) identify common variables; (3) construct a data dictionary; (4) construct a harmonized
dataset; (5) analyze the data; (6) discuss the results; and (7) prepare scientific articles.
The data sharing and joint analyses of the ZBC Consortium will contribute to under-
standing of congenital Zika and will specifically enable a larger sample size and more
robust estimates, an increased ability to quantify risks associated with rare events, and
identification and quantification of sources of heterogeneity, if any exist.
2. ZBC Consortium Protocol
2.1. Objectives
The main objective of the ZBC Consortium is to jointly analyze data from Brazilian
cohorts of pregnant women and children to obtain a more accurate estimation of the
absolute risk of congenital Zika and a better characterization of the full spectrum of the
syndrome among affected children with and without microcephaly.
Two groups of prospective cohorts will be analyzed. The first group includes studies
of pregnant women with rash (i.e., a common symptom of acute ZIKV infection) and will
estimate the absolute risk of adverse outcomes compatible with exposure to ZIKV during
pregnancy, by trimester at which infection occurred. The joint analysis of the cohorts of this
group will be conducted in two steps. In the first step, we will estimate the absolute risk
in children born to women who tested RT-PCR-positive for ZIKV during pregnancy for
the following adverse outcomes: microcephaly, brain imaging abnormalities, neurological
abnormalities and ophthalmological disorders. For the outcomes of microcephaly, brain
imaging abnormalities, neurological abnormalities, and ophthalmological disorders, the
absolute risk will be estimated for each outcome separately, for the presence of at least
one of these outcomes, and, finally, for the concomitant presence of two or more of these
abnormalities combined in different ways. This analysis will be performed using the
findings at birth/first evaluation and, for the subset of children who were included in
the children’s cohort, at any time during the follow-up. A subsequent analysis will be
conducted to compare the relative risk of these outcomes in children born to women
who tested RT-PCR-positive for ZIKV during pregnancy of the ZBC Consortium with
the risk in children born to Brazilian unexposed mothers of the International Prospective
Observational Cohort Study of Zika in Infants and Pregnancy (ZIP Study) [21]. This
comparison will allow us to estimate the strength of the association and the excess risk of
adverse outcomes in the exposed group compared to the unexposed.
The second group is composed of the cohorts of children with microcephaly and/or
other adverse outcomes compatible with exposure to ZIKV and children born to mothers
of the ZBC pregnant women cohorts, and its analysis aims to characterize the spectrum of
clinical features, brain imaging abnormalities, ophthalmological disorders, neurological
manifestations and neurocognitive development in these children. To characterize the full
spectrum of congenital Zika manifestations, three groups of children will be compared:
children with Zika-related microcephaly, children with other adverse outcomes compatible
with exposure to ZIKV during pregnancy, and asymptomatic children born to women
with laboratory evidence of ZIKV infection during pregnancy. A subsequent analysis
will be carried out in which the ZIKV-exposed children of the ZBC Consortium will be
compared with unexposed Brazilian children in the ZIP Study in relation to the type of
abnormalities and their evolution, and in relation to the anthropometric measures and
neurodevelopment.
Though the inclusion of the unexposed children of the ZIP study will provide a
baseline-type comparison with a sample representative of the general population, there are
some limitations in these comparisons. They are mainly related to differences in the forms
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and instruments to evaluate the children, the time gap in the beginning of the studies and
the greater territorial coverage of the ZBC Consortium. In contrast to the ZIP study in
which the teams who evaluated the children were blind to exposure status of the mothers
and their offspring, for most of the cohorts of the ZBC Consortium, these teams knew
that the children were born to women who presented symptoms compatible with Zika
virus infection during pregnancy. To deal with the possibility of misclassification of the
outcome, we will conduct a sensitivity analysis using different definitions. In relation
to the potential difference in the frequency of abnormalities in children in the reference
population of each cohort, we will also perform a sensitivity analysis restricted to exposed
and unexposed children living in the same area. Concerning the time gap, it is not likely
that the frequency of abnormal outcomes in the reference population would vary within
this length of time. Finally, although there was a standardized protocol for the evaluation of
children in cohorts, we cannot rule out that the children in the ZBC Consortium, being born
to women who presented symptoms, were not more carefully investigated, which could
lead to an overestimate in the difference between the exposed and unexposed groups.
2.2. Study Population, Eligibility and Inclusion Criteria
For the meta-analysis of the cohorts of pregnant women, studies were eligible to be
included if they were based in Brazil and had recruited pregnant women with rash and
laboratory evidence of acute ZIKV infection. Due to the potential for serological cross-
reactivity, the main analysis will be restricted to pregnant women who tested positive for
ZIKV by reverse transcription polymerase chain reaction (RT-PCR). Additional sensitivity
analyses will be conducted including women who tested positive for ZIKV by other
laboratory criteria, including: seroconversion during pregnancy (assessed at two time
points by immunoglobulin (Ig) M, IgG, IgG3 or plaque reduction neutralization test (PRNT))
or symptoms (rash) plus at least one positive test result (IgM or PRNT) [12].
For the joint analysis of the children’s cohorts, Brazilian studies that had recruited
children with congenital Zika manifestations or children born to pregnant women who had
laboratory evidence of acute ZIKV infection as described above were considered eligible.
Laboratory tests for ZIKV infection were not performed for all children and, for those who
were tested, there was a variation in the biological specimen used, cerebrospinal fluid and
blood samples being tested, respectively, for children with and without microcephaly. For
these reasons and for the limitations of the diagnostic tests, children were categorized
in groups according to different levels of evidence. Children with congenital Zika mani-
festations were classified into four categories: (i) definitive—with laboratory evidence of
infection in the mother during pregnancy or in the newborn by serology, PRNT or RT-PCR,
regardless of other findings; (ii) highly probable—imaging with specific features related
to structural abnormalities in brain tissue, and negative laboratory testing for syphilis,
toxoplasmosis and cytomegalovirus; (iii) moderately probable—imaging with specific
features, but without results for one or more of the three infections (syphilis, toxoplasmosis
and cytomegalovirus); (iv) somewhat probable cases—children for whom there was a
report of imaging abnormality without detailed descriptions of findings but a physician of
the research team concluded that a congenital infection was probably involved, and for
whom laboratory results for syphilis, toxoplasmosis or cytomegalovirus were negative
or unavailable [22]. Whereas somewhat probable cases were excluded from the primary
analysis, moderately and highly probable cases were included because it has recently been
shown that negative PRNT result does not exclude diagnosis of ZIKV infection [23]. The
Microcephaly Epidemic Research Group (MERG) Pregnant Women’s Cohort showed that
among ZIKV RT-PCR-positive mothers, less than half (48.5%), had a positive PRNT [12].
A subsequent analysis of the Pregnant Women Cohorts and of the Children Cohorts
will include a comparison group of unexposed children from the ZIP Study who tested
negative at birth and who were born to women who tested negative for ZIKV repeatedly
(i.e., by RT-PCR and IgM) during pregnancy and until the 6th week after delivery [21]. Only
the data of the Brazilian children and their mothers in this multi-country investigation will
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be analysed. These children underwent anthropometric, neurological and ophthalmologic
analyses according to a standardised protocol and were followed up until the end of the
first year of life.
2.3. Outcome Measures
The adverse outcomes assessed in the two meta-analyses will be the presence of micro-
cephaly, brain imaging and neurological abnormalities, ophthalmological disorders, small
for gestational age births, and stillbirth. Each of these summary outcomes was constructed
based on the presence of specific clinical indicators and, in subsidiary analyses, we ana-
lyzed the risks of component adverse outcomes. For microcephaly, we will investigate both
severity and proportionality. For neurological abnormalities, we will observe the presence
of altered consciousness level/behaviour, inadequate visual or hearing response, localized
motor deficit, abnormal tonus/trophism, sign of pyramidal release, and seizures. The brain
imaging abnormalities will include the presence of calcification, ventriculomegaly, diffuse
cortical atrophy, and other structural alterations. For ophthalmological disorders, we will
consider the alterations of retina, optic nerve and fundus.
2.4. Length of Follow-Up
Pregnant women were evaluated at least once during pregnancy. Their offspring
were evaluated at least once at birth or in the first months after delivery. For the children
included in the Children’s cohorts meta-analysis, the length of follow up varied in the
different studies, with the longest period of follow-up being up to 4 years.
2.5. Sample Size
All Brazilian cohorts that met the inclusion criteria were included in the analysis
independent of the sample size. As the full spectrum of manifestations compatible with
ZIKV exposure during pregnancy is not known and some rare events may not have yet
been identified, a larger sample size in the joint analysis will increase the chance to detect
these events. In the meta-analysis, the option to perform a one-stage analysis was based on
its suitability to work with rare events [24].
2.6. Study Identification, Data Sources, and Data Storage
The ZBC Consortium sought to identify all Brazilian cohorts of pregnant women with
rash possibly associated with ZIKV infection and cohorts of children with microcephaly
and/or other manifestations of congenital Zika. To this end, all groups that received
funding from the Brazilian National Council for Scientific Research and Development
(Conselho Nacional de Desenvolvimento Científico e Tecnológico-CNPq), the Coordination
for the Improvement of Higher Level-Education Personnel (Coordenação de Aperfeiçoa-
mento de Pessoal de Nível Superior - CAPES) and the Brazilian Ministry of Health were
contacted regarding their research related to ZIKV infection. Those who participated in the
harmonization meetings of research instruments and protocols hosted by PAHO/WHO in
Recife (March 2016), Mexico (June 2016), and Geneva (February 2017) were also invited. All
identified groups were asked to refer other cohort studies that were not on the list initially
raised. In total, 12 cohorts of pregnant women and 15 cohorts of children followed by 16
research groups are included in the ZBC Consortium. The cohorts represent the North,
Northeast, Middle-West and Southeast regions of Brazil (Figure 1).
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Figure 1. Municipalities with Brazilian cohorts of pregnant women and cohorts of children, partici-
pating in the ZBC Consortium.
Due to the participation of Brazilian groups in both the ZBC Consortium and the ZIP
Study, it will be possible to include all Brazilian ZIP sites, i.e., Recife and Salvador in the
Northeast, and Rio de Janeiro and Ribeirão Preto in the Southeast, in the analysis.
2.7. Extraction of Data
The same procedures were applied to collect individual participant data from the
pregnant women and children’s cohorts. Participating cohorts provided all questionnaires
and case report forms, which were searched to identify variables relevant to the proposed
objectives and common to all studies. For the cohorts of pregnant women, variables pro-
viding the following information were selected: characteristics of pregnancy and infection;
laboratory tests for diagnosis of ZIKV infection; birth outcomes: children’s head circum-
ferences and anthropometric measurements, brain imaging abnormalities, morphological
characteristics, and clinical, neurological, ophthalmological and hearing alterations. For the
cohorts of children, in addition to the outcomes described above, variables related to neu-
rocognitive development and electroencephalogram (EEG) were selected. Data related to
repeated measures were collected to evaluate the evolution of the different manifestations
of congenital Zika.
All the cohort databases were first standardized by each research team using specially
developed data collection tools (i.e., a baseline questionnaire and a data dictionary (defining
the formats and categorization of variables)), which facilitated the sharing of harmonizable
databases. Then, in a secure “Shared Data Platform,” the databases of all associated cohorts
were jointly stored. The creation of this platform and its management structures reflected
the diversity and complexity of data from different sources and formats (e.g., imaging
findings) that needed to be stored, analyzed and shared. The development software used
for the platform was GeneXus X Ev 1, which develops web environment applications using
aspx code. The Informatics Sector of the Aggeu Magalhães Institute/Fiocruz/Pernambuco
designed and protected the Shared Data Platform. All data were anonymized and protected
by password. Access was restricted to the ZBC Consortium coordinators.
The ZIP Study dataset will be harmonized with the ZBC Consortium dataset following
the same standardization. The ZIP Study dataset has most of the critical variables of the
ZBC Consortium. Exposed and unexposed mothers and children were followed using the
same standardized protocol except for transfontanelar ultrasound, which was performed
mainly on the children born to exposed mothers.
2.8. Analysis Plan
The ZBC Consortium Analysis Committee will synthesize the individual participant
data from the two groups of cohort studies.
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2.8.1. Descriptive Analysis
Aggregate descriptions of the individual participants in the cohorts will be provided.
For the cohorts of pregnant women and children, analyses will include descriptions of
covariate frequencies and distributions. For quantitative variables, including: head circum-
ference at beginning and at other moments of reevaluation; mean head circumference of
children with microcephaly; mean head circumference of children with other anomalies
of congenital Zika; mean head circumference of babies born to mothers exposed during
pregnancy, measures of central tendency and dispersion will be presented. For categorical
variables, relative frequency distributions will be shown like the proportion of children
with adverse outcomes at baseline and subsequent reevaluations among children with
microcephaly, with other abnormalities of congenital Zika and children of the cohorts of
mothers exposed during pregnancy.
2.8.2. Individual Participant Data Meta-Analyses for Absolute Risks
An Individual Participant Data Meta-Analysis will be undertaken to estimate the
absolute risk of having children with congenital Zika manifestations among women in-
fected with ZIKV during pregnancy. To estimate the overall proportion and 95% confidence
intervals of congenital Zika manifestations, we will first use a one-stage approach.
In the one-stage analysis, we will use a hierarchical model with a random effect to
account for the clustering of patients within studies. As a sensitivity analysis and to assess
the heterogeneity parameter between studies for some key variables, we will also use a
two-stage approach. In the two-stage analysis, we will first estimate the study-specific
proportions with 95% score confidence intervals. We will then estimate the overall pooled
proportion with 95% Wald confidence intervals using the Metaprop command in STATA
and investigate heterogeneity between study sites with the I2 statistic [25].
2.8.3. Individual Participant Data Meta-Analyses for Relative Risks
The comparison of different groups and the introduction of a control group will allow
the estimation of the measures of association, i.e., odds ratio and attributable risk. The
primary analysis for binary outcomes will be a meta-analysis of one-stage individual data
with a random intercept (i.e., considering intra-site correlations) and random effect of ZIKV
infection (rather than a fixed effect, therefore considering heterogeneity between sites).
This model will use maximum square likelihood. Exposure and outcome variables will be
coded as 1/0.
The choice to conduct a one-stage analysis was motivated by the following reasons:
rare results (i.e., studies with less than 5 outcome events) may be included; a small number
of studies may be included (i.e., addressing situations when a particular outcome has not
been measured at all sites); additional adjustments for possible confounders and effect mod-
ifiers can be made easily; the exact binomial distribution of data in each study is modeled
without correction; and the correlations of intra-study parameters are considered [26].
Odds ratio for the association of ZIKV infection during pregnancy according to
the trimester of infection, and congenital Zika manifestations will be estimated using
random effects multilevel logistic regression models (i.e., using melogit in STATA). Thus,
odds ratios for stillbirths, newborns with microcephaly, brain calcifications in the absence
of microcephaly, other abnormalities of central nervous system development and other
malformations will also be estimated. The model may be sequentially adjusted for potential
confounders. Case definitions will be investigated using sensitivity analyses. Heterogeneity
will be investigated using subgroup analyses. Effect modification will be evaluated by the
likelihood ratio test.
2.8.4. Meta-Analysis of Two- and One-Stage Individual Data
Associations between maternal ZIKV infection and ongoing continuous outcomes
(e.g., head circumference z-scores) will be investigated using both meta-analysis of two-
and one-stage individual data. For the two-stage individual participant data meta-analysis
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approach, we will first fit an analysis of the covariance model to the participants’ individual
data from each study site separately. Next, we will perform a random effects meta-analysis
of the ANCOVA results from each study using the restricted maximum likelihood estimate.
Confidence intervals will be estimated with Hartung–Knapp correction. For the single-
stage meta-analysis approach, we will fit random effects ANCOVA (i.e., mixed linear
model) with a random intercept (i.e., considering intra-site correlations) and random effects
of ZIKV infection. This model will use the restricted maximum likelihood estimate and
employ a Kenwood Roger confidence interval correction.
We will also investigate time-to-event outcomes (e.g., time to first seizure) using
a study-site stratified one-stage Cox regression model, thus allowing for the study of
site-specific baseline risk functions.
All p-values will be from two-tailed statistical tests, and all analyses will be performed
using Stata, version 15.1 (StataCorp LP, College Station, TX, USA)
2.8.5. Comparison of Subgroups of Children
To characterise the full range of defects and disabilities that may be associated with
congenital Zika and their proportional distribution, four groups of children will be com-
pared: (i) children with microcephaly; (ii) children without microcephaly but with symp-
toms compatible with congenital Zika; (iii) asymptomatic children born to mothers with
laboratory evidence of Zika virus infection during pregnancy; and (iv) children born to
unexposed mothers.
In the group with microcephaly we will describe all the Zika-related abnormalities
and the frequency in which they occur, building the spectrum of the Congenital Zika
Syndrome. In the group of children without microcephaly but with symptoms compatible
with congenital Zika), we will describe the type of abnormality and their proportional
distribution, either isolated or in combination, building the spectrum of congenital Zika in
children without microcephaly. The frequency of abnormalities will be compared in these
two groups. In the group of children born to women with laboratory evidence of Zika
infection during pregnancy but asymptomatic, we will describe the frequency of neurode-
velopment delay, which may also be a manifestation of congenital Zika, and compare with
the other groups. In the group of children born to unexposed mothers, we will describe the
frequency and type of abnormality, if any, and assess their neurodevelopment. This group
will be compared with all others, being the standard for the comparisons. Anthropometric
measures will also be compared between groups and within groups over time. To estimate
the change in head circumference (z-score), weight (z-score) and height (z-score) over time
and to estimate the mean difference in Z-scores between clinically relevant subgroups, we
will use multilevel mixed effects models accounting for within-child and within-study
correlations.
To test the significance of the differences in frequency between groups we will use the
Chi-square or the Fisher test, when indicated, and for the comparison of means we will use
the F-test or the equivalent nonparametric test.
2.9. Ethical Considerations
All participating cohort studies had ethical approval: CAAE 52675616.0.0000.5192;
CAAE 53240816.4.0000.5190; CAAE 52803316.8.0000.5192; CAAE 54734316.5.0000.5208;
CAAE 52888616.4.0000.5693; CAAE 57792616.1.0000.5030; CAAE 51889315.7.0000.0040;
CAAE 65897317.1.0000.5086; CAAE 53611316.0.00005546; CAAE 60168216.2.0000.0005;
CAAE 56969516.8.0000.0019; CAAE 68067217.0.0000.0019; CAAE 29124920.6.0000.0019;
CAAE 64534017.7.0000.5083; CAAE 56176616.2.1001.5327; CAAE 52675616.0.0000.5269;
CAAE 0026.0.009.000-07; CAAE 55465616.0.0000.5275; CAAE 54497216.2.1001.5264; CAAE
56522216.0.0000.5440; CAAE 55805516.2.0000.5415; and CAAE 53248616.2.0000.5412. All
participating pregnant women and persons responsible for participating children provided
written informed consent form.
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3. Public Involvement
We held periodical meetings of the principal investigators of the different cohorts to
discuss the results of the preliminary analyses and to suggest further points to be explored.
Representatives of the Ministry of Health participated in all these meetings and have access
to the results and discussions that could inform their guidelines and policies. The final
results will also be presented and discussed with local and national health authorities
(Secretariats of Health and Ministry of Health) in order to support the adoption of specific
public policies aimed at this population.
4. ZBC Consortium Governance
With the facilitation and support of the Brazilian Ministry of Health, the governance
model of the ZBC Consortium was achieved after agreement between researchers. Briefly,
the Executive Secretariat, with regional representation from the research groups, coor-
dinates the consortium and responds directly to the Collegiate, which is composed of
representatives from each research group. Under the Collegiate, there is an Analysis
Committee that oversees data management and the joint analyses on behalf of the entire
Consortium. Members of the Executive Secretariat were elected, and members of the
Analysis and Writing Committees were appointed in Collegiate meetings. Representatives
of the Ministry of Health (SCTIE, SVS and SAS) are both facilitators and members of the
Collegiate. The ZBC Consortium was established based on three principles: decisions are
made by consensus between partners, there is no hierarchy between groups, and research
groups will lead all initiatives.
5. Discussion and Conclusions
The ZBC Consortium will bring together individual participant data in order to op-
timize the use of existing epidemiological evidence related to ZIKV infections during
pregnancy and congenital Zika manifestations among populations in Brazil. The harmo-
nized database will enable more robust epidemiological analyses that will yield integrated
views of this important public health problem. The meta-analyses of individual participant
data from the various cohorts in Brazil will create a larger sample size that will facilitate
the more precise estimation of congenital Zika manifestations risks and will enable in-
vestigation of rare sequelae. In addition, by integrating data from cohorts from different
geographic locations and populations across Brazil, this study will enable robust investiga-
tions that will improve understanding of the sources of heterogeneity between individual
cohort studies. Furthermore, this study will help to overcome challenges arising from
the different case definitions used in the published literature to date to identify prenatal
ZIKV exposure and congenital Zika-related outcomes. Specifically, this study’s planned
sensitivity analyses will make it possible to explore the impact of using different definitions
of exposure and categories of outcomes in the estimation of congenital Zika manifestations.
In addition to facilitating investigations of established hypotheses, this integrated data
platform, with its wealth of information, will also allow the investigators to explore new
scientific questions as they arise in the future. The ZBC Consortium will strengthen national
partnerships, and the information obtained from this joint study will inform public health
policies related to ZIKV.
We believe that this protocol provides a well-developed, consistent methodology that
will be a valuable resource for consistent analysis of disparate sets of data in order to gain
a better understanding of the impact of ZIKV infection on pregnant women and their
children. This is a reference tool for future studies that are expected to fill in any gaps and
presumably refine the methodology. As such, this paper is a resource and will add value
in understanding the impact of ZIKV infection during pregnancy. It may also serve as a
model to enhance the preparedness of researchers investigating new emerging infectious
disease epidemics in the future.
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